Solid Biosciences has dosed the first participant in its Phase 3 IMPACT DUCHENNE trial, testing the gene therapy SGT-003 for Duchenne muscular dystrophy. This placebo-controlled, randomized, double-blind study aims to provide robust data to support regulatory approval globally. The therapy has shown good safety in earlier trials, with 46 participants dosed and no serious adverse effects reported. The trial is a key step toward offering a new treatment option for this severe genetic muscle disease, with sites active in multiple countries and further expansions planned.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
DMG Blockchain Solutions announced two strategic investments: one in MeetAmi Innovations, a Canadian fintech offering digital asset wealth management platforms, and another in Atomic47 Labs, an AI company focused on secure, sovereign AI infrastructur...
